<DOC>
	<DOCNO>NCT01302873</DOCNO>
	<brief_summary>This study assess efficacy two week treatment BGG492 patient chronic subjective Tinnitus .</brief_summary>
	<brief_title>Study BGG492 Patients With Chronic Subjective Tinnitus</brief_title>
	<detailed_description />
	<mesh_term>Tinnitus</mesh_term>
	<criteria>Patients diagnose THI ( Tinnitus Handicap Inventory ) severity grade 3 , 4 5 ( moderate , severe catastrophic ) , chronic ( &gt; 6 month &lt; 36 month ) subjective tinnitus Willing abstain activity require focused attention , e.g . drive car vehicle , operate machine engage potentially dangerous activity require focused attention intact physical balance Willing able refrain engage activity work involve loud noise exposure Patients diagnose tinnitus THI severity grade equal 2 1 Patients diagnosis intermittent pulsatile tinnitus Patients tinnitus concomitant symptom treatable otological disease ( otitis medium , Meni√®re 's disease , otosclerosis ) , neurological tumor or/and temporomandibular joint disorder Patients history frequent middle ear infection ( &gt; 3 infection per year last 3 year ) Patients diagnose anxiety disorder , depression , schizophrenia significant psychiatric disease require current drug treatment patient require treatment previous 3 month disease . Patients current unilateral bilateral hearing loss 75 dB one test frequency ( 125 Hz , 250 Hz , 1 kHz , 2 kHz , 4 kHz , 6 kHz , 8 kHz ) Patients Vestibular Schwannoma Patients cochlear implant Patients regular intake central nervous system act drug treatment tinnitus previous 6 month prior initial dose Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tinnitus</keyword>
	<keyword>AMPA Receptor antagonist</keyword>
</DOC>